ERBB2(HER2)融合:分析数据显示,中国NSCLC患者中ERBB2融合的发生率为0.29%。部分患者使用阿法替尼治疗有效[85]。. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.